



## Vonvendi<sup>®</sup> [von Willebrand factor (recombinant)] – Expanded indication

- On April 17, 2018, [Shire announced](#) the FDA approval of [Vonvendi \[von Willebrand factor \(recombinant\)\]](#) for perioperative management of bleeding in adults (age 18 and older) diagnosed with von Willebrand disease (VWD).
  - Previously, Vonvendi was indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with VWD.
- According to the [National Hemophilia Foundation](#), VWD affects up to 1% of the U.S. population, and is the most common bleeding disorder.
- The efficacy of Vonvendi in perioperative management of bleeding was assessed in an open-label trial of 15 patients with VWD who underwent surgery. Patients were allowed the use of [Advate<sup>®</sup> \[antihemophilic factor \(recombinant\)\]](#) in addition to Vonvendi. Hemostatic efficacy was measured on a 4-point efficacy scale (excellent, good, moderate, and none) where a rating of excellent or good was required to declare the outcome a success.
  - Overall hemostatic efficacy was 100% (90% CI: 81.9%, 100%).
- The most common adverse reactions ( $\geq 2\%$ ) with Vonvendi use were generalized pruritus, nausea, and dizziness.
  - One subject treated with Vonvendi in the perioperative setting developed deep vein thrombosis after undergoing total hip replacement surgery.
- For perioperative management of bleeding, dosage and frequency of Vonvendi must be individualized according to clinical judgement, weight, type and severity of the bleeding episodes/surgical intervention, and clinical and laboratory measures.
- Refer to the Vonvendi prescribing information for full dosing information for both indications.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.